Efficacy of postoperative antiviral combined transcatheter arterial chemoembolization therapy in prevention of hepatitis B-related hepatocellular carcinoma recurrence

被引:0
|
作者
YAN Qiang [1 ,2 ]
NI Jun [2 ]
ZHANG Guo-lei [2 ]
YAO Xing [2 ]
YUAN Wen-bin [2 ]
ZHOU Lin [1 ]
ZHENG Shu-sen [1 ]
机构
[1] Division of Hepatobiliary and Pancreatic Surgery,First Affiliated Hospital,Zhejiang University School of Medicine
[2] Department of Hepatobiliary and Pancreatic Surgery,Huzhou Central Hospital
关键词
D O I
暂无
中图分类号
R735.7 [肝肿瘤];
学科分类号
100214 ;
摘要
Background Recurrence of hepatitis B-related hepatocellular carcinoma(HCC) after curative resection is the leading factor influencing the prognosis of the disease.Therefore,further improvement of long-term survival may depend on the prevention and treatment of the recurrent tumor.The aim of this research was to investigate the role of antiviral therapy and postoperative transcatheter arterial chemoembolization(TACE) in the prevention and treatment of hepatitis B-related HCC recurrence.Methods One hundred and twenty patients who underwent curative resection of hepatitis B-related HCC between January 2005 and June 2008 at our hospital were enrolled.Patients were divided into four groups according to the post-operative adjuvant therapy they received,i.e.,control,antiviral therapy group,TACE group,and combined group.The disease-free survival(DFS) and the 12-,24-,36-month cumulative recurrence rates were studied.Results There was no significant difference between isolated postoperative antiviral therapy group and control in terms of disease-free survival(P=0.283),while it was significantly higher in the TACE group compared to control(P=0.019).In all patients,however,viral prophylactic therapy combined with/without TACE brought a favorable result compared to those only with/without TACE(P <0.001).Similarly,no matter combined with or without antiviral treatment,postoperative TACE prolonged DFS(P=0.015).Naturally,a combination of viral prophylactic therapy on the baseline TACE significantly benefited patients’ postoperative DFS(P=0.047) and vice verse(P=0.002).The 24-month cumulative recurrence rates of combined group were significantly lower than that of isolated control group and antiviral therapy(P<0.001 and P=0.011respectively).However,36-month recurrence rate was significantly different in the control group compared to the TACE group and combined group(P=0.040 and 0.002 respectively);same as the antiviral group compared to the combined group(P=0.034).Conclusions Post-operative TACE prevents early recurrence while antiviral therapy prevents late recurrence of HCC.Combination of antiviral therapy and TACE are suggested for prevention in HCC patients with high risk of recurrence.
引用
收藏
页码:855 / 859
相关论文
共 50 条
  • [31] Antiviral Therapy and Hepatitis B Virus-Related Hepatocellular Carcinoma Recurrence Reply
    Wu, Chun-Ying
    Hsu, Yao-Chun
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (08): : 766 - 767
  • [33] Successful management of postoperative recurrence of hepatocellular carcinoma with p53 gene therapy combining transcatheter arterial chemoembolization
    Guan, Yong-Song
    Liu, Yuan
    Sun, Long
    Li, Xiao
    He, Qing
    WORLD JOURNAL OF GASTROENTEROLOGY, 2005, 11 (24) : 3803 - 3805
  • [34] Efficacy of Transcatheter Arterial Chemoembolization (TACE) combined with sorafenib in the treatment of advanced hepatocellular carcinoma
    Wu, Jian-Bing
    Xu, Guan-Jun
    Lu, Yu-shan
    Huang, Long-zhang
    Cai, Sheng
    Li, Lin
    Jiang, Wei-Min
    AFRICAN JOURNAL OF PHARMACY AND PHARMACOLOGY, 2012, 6 (34): : 2515 - 2519
  • [35] Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma
    Wong, J. S. -W.
    Wong, G. L. -H.
    Tsoi, K. K. -F.
    Wong, V. W. -S.
    Cheung, S. Y. -S.
    Chong, C. -N.
    Wong, J.
    Lee, K. -F.
    Lai, P. B. -S.
    Chan, H. L. -Y.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (10) : 1104 - 1112
  • [36] Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma
    Wu, Jaw-Ching
    Huang, Yi-Hsiang
    Chau, Gar-Yang
    Su, Chien-Wei
    Lai, Chung-Ru
    Lee, Pui-Ching
    Hu, Teh-Ia
    Sheen, I-Jane
    Lee, Shou-Dong
    Lui, Wing-Yiu
    JOURNAL OF HEPATOLOGY, 2009, 51 (05) : 890 - 897
  • [37] Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma
    Honda, Yohji
    Kimura, Tomoki
    Aikata, Hiroshi
    Kobayashi, Tomoki
    Fukuhara, Takayuki
    Masaki, Keiichi
    Nakahara, Takashi
    Naeshiro, Noriaki
    Ono, Atsushi
    Miyaki, Daisuke
    Nagaoki, Yuko
    Kawaoka, Tomokazu
    Takaki, Shintaro
    Hiramatsu, Akira
    Ishikawa, Masaki
    Kakizawa, Hideaki
    Kenjo, Masahiro
    Takahashi, Shoichi
    Awai, Kazuo
    Nagata, Yasushi
    Chayama, Kazuaki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 (03) : 530 - 536
  • [38] Combined therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation for small hepatocellular carcinoma
    Yang, Wei-Zhu
    Jiang, Na
    Huang, Ning
    Huang, Jing-Yao
    Zheng, Qu-Bin
    Shen, Quan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (06) : 748 - 752
  • [39] Stereotactic Body Radiation Therapy Combined with Transcatheter Arterial Chemoembolization for Small Hepatocellular Carcinoma
    Aikata, Hiroshi
    Hiramatsu, Akira
    Tsuge, Masataka
    Kawaoka, Tomokazu
    Imamura, Michio
    Murakami, Eisuke
    Chayama, Kazuaki
    HEPATOLOGY, 2018, 68 : 544A - 545A